Abstract

To probe the clinical efficacy of rituximab combined with cyclophosphamide, adriamycin, vincristine together with prednisone regimen sequential or non-sequential local radiotherapy in patients with stage III-IV diffuse large B-cell lymphoma. The clinical data of 126 patients with high-risk diffuse large B-cell lymphoma in the First Affiliated Hospital of Hainan Medical University from January 2018 to December 2021 were retrospectively analyzed. Among them, the patients in the cyclophosphamide, adriamycin, vincristine together with prednisone group were adopted cyclophosphamide, adriamycin, vincristine together with prednisone regimen, the patients in the radiotherapy group were adopted radiotherapy in addition to cyclophosphamide, adriamycin, vincristine together with prednisone regimen and the patients in the combined group were treated with rituximab in addition to the radiotherapy group. The short-term and long-term efficacy, adverse reactions and immunoglobulin levels were compared in these three groups. In comparison with cyclophosphamide, adriamycin, vincristine together with prednisone group, the total effective rate of combined group and radiotherapy group was elevated and the whole effective rate of combined group was increased relative to radiotherapy group. Spearman correlation analysis unveiled that the clinical efficacy of the radiotherapy group together with the combined group was negatively correlated with the serum immunoglobulin M level after 4 courses and 6 courses of treatment. Rituximab combined with radiotherapy is effective in diffuse large B-cell lymphoma therapy, which can significantly promote the short-term efficacy of patients with high safety.